ECE2006 Poster Presentations Clinical case reports (128 abstracts)
1University Department of Diabetes & Endocrinology, Clinical Scienes Centre, University Hospital Aintree, Liverpool L9 7AL, United Kingdom; 2Walton Centre for Neurology & Neurosciences, Liverpool, United Kingdom.
Objectives: Prolactinomas can extend out of the sella turcica and invade surrounding structures and the brain. The prevalence and natural history of epilepsy at presentation of macroprolactinoma is not clear.
Methods: The case records of 62 patients (34 male) with macroprolactinoma attending a neuroendocrine clinic were studied.
Results: Four patients (6.5%, 3 males) had experienced epileptic seizures before the diagnosis of macroprolactinoma was made. The details at diagnosis are shown below:
Age | Sex | Prolactin mU/l | MRI appearance | Epilepsy time present |
33 | M | 30,000 | Indents 3rd ventricle | Grandmal, 3 months |
42 | M | >500,000 | Invades temporal lobe | Simple partial, 7 years |
51 | M | >750,000 | Invades temporal lobe | Complex partial, 23 years |
52 | F | >400,000 | Invades temporal lobe | Complex partial, 2 years |
One patient (42 M) had simple partial seizures which was undiagnosed for 7 years prior to the diagnosis of macroprolactinoma. Another (51 m) had monthly, complex partial seizures and was on antiepileptic treatment for 23 years. A CT scan in 1982 was reported as normal but MRI scan in 2004 showed massive, invasive prolactinoma. His seizures stopped with bromocriptine treatment although MRI appearance is unchanged.
Conclusion: Patients with macroprolactinomas should be questioned about possible epilepsy especially partial seizures, which may be present for many years before diagnosis. Dopamine agonist treatment may reduce seizure frequency.